Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes
    21.
    发明授权
    Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes 有权
    对抗耐药微生物有效的利福霉素C-11肟环衍生物

    公开(公告)号:US07265107B2

    公开(公告)日:2007-09-04

    申请号:US11076173

    申请日:2005-03-09

    申请人: Jing Li Zhenkun Ma

    发明人: Jing Li Zhenkun Ma

    CPC分类号: C07D498/18

    摘要: The current invention relates to a series of rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms, specifically, the 3,4-cyclo-rifamycin derivatives having an oxime group at the C-11 position.

    摘要翻译: 本发明涉及一系列具有抗菌活性的利福霉素衍生物,包括抗药性微生物的活性,具体地说,具有C-11位上肟基的3,4-环 - 利福霉素衍生物。

    C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes
    22.
    发明授权
    C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes 有权
    C-25氨基甲酸酯利福霉素衍生物,具有抗药性的微生物活性

    公开(公告)号:US07250413B2

    公开(公告)日:2007-07-31

    申请号:US11114384

    申请日:2005-04-26

    摘要: Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to C-25 carbamate derivatives of rifamycin having another functional group or pharmacophore covalently attached to this position through a carbamate linkage. The resulting compounds exert their antimicrobial activity through a dual-function mechanism and therefore exhibit reduced frequency of resistance.

    摘要翻译: 本发明的化合物涉及具有抗微生物活性的利福霉素衍生物,包括抗耐药微生物的活性。 更具体地,本发明的化合物涉及具有另一官能团的利福霉素的C-25氨基甲酸酯衍生物或通过氨基甲酸酯键共价连接到该位置的药效团。 所得化合物通过双功能机制发挥其抗微生物活性,因此表现出降低的抗性频率。

    Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes
    24.
    发明申请
    Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes 有权
    对抗耐药微生物有效的利福霉素C-11肟环衍生物

    公开(公告)号:US20050203085A1

    公开(公告)日:2005-09-15

    申请号:US11076173

    申请日:2005-03-09

    申请人: Jing Li Zhenkun Ma

    发明人: Jing Li Zhenkun Ma

    IPC分类号: A61K31/5383 A61K31/5415

    CPC分类号: C07D498/18

    摘要: The current invention relates to a series of rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms, specifically, the 3,4-cyclo-rifamycin derivatives having an oxime group at the C-11 position.

    摘要翻译: 本发明涉及一系列具有抗菌活性的利福霉素衍生物,包括抗药性微生物的活性,具体地说,具有C-11位上肟基的3,4-环 - 利福霉素衍生物。

    11-deoxy azalide antibacterials
    25.
    发明授权
    11-deoxy azalide antibacterials 有权
    11-deoxy azalide抗菌剂

    公开(公告)号:US06933283B2

    公开(公告)日:2005-08-23

    申请号:US10421577

    申请日:2003-04-23

    IPC分类号: C07H17/08 A61K31/70

    CPC分类号: C07H17/08

    摘要: Antibacterial compounds having formula (I) and formula (II) and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and methods for prophylaxis or treatment of bacterial infections using the compounds are disclosed.

    摘要翻译: 具有式(I)和式(II)的抗菌化合物及其前体药物的盐,前药和盐,用于制备本方法中使用的化合物和中间体的方法,含有该化合物的组合物,以及用于预防或治疗细菌感染的方法 公开了这些化合物。

    Rifamycin derivatives
    29.
    发明授权
    Rifamycin derivatives 有权
    利福霉素衍生物

    公开(公告)号:US07229996B2

    公开(公告)日:2007-06-12

    申请号:US11186187

    申请日:2005-07-21

    CPC分类号: C07D401/12 C07D455/02

    摘要: Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C1-C4) forms): or their salts, hydrates or prodrugs thereof, wherein: a preferred R comprises hydrogen, acetyl; L is a linker, a preferred linker group elements selected from any combination of 1 to 5 groups shown FIG. 1, provided L is not wherein R1 is H, methyl or alkyl. The inventive compounds exhibit valuable antibiotic properties. Formulations having these compounds can be used in the control or prevention of infectious diseases in mammals, both humans and non-humans. In particular, the compounds exhibit a pronounced antibacterial activity, even against multiresistant strains of microbes.

    摘要翻译: 式I的新型利福霉素衍生物(氢醌和相应的醌(C 1 -C 4))形成):或其盐,水合物或前药,其中:优选的R 包括氢,乙酰基; L是接头,优选的连接基团元素选自1至5个组的任何组合,如图1所示。 1,其中L不是其中R 1是H,甲基或烷基。 本发明化合物显示出有价值的抗生素性质。 具有这些化合物的制剂可以用于控制或预防哺乳动物,包括人和非人的感染性疾病。 特别地,这些化合物甚至显示出显着的抗菌活性,即使是针对多抗菌菌株的微生物。